Mirati Therapeutics Jumps 20% On Positive Study Results Of Adagrasib For NSCLC

Shares of Mirati Therapeutics, Inc. (MRTX) are jumping over 20% on Tuesday morning driven by the positive results of adagrasib for treatment of NSCLC.

MRTX is currently trading at $52.31, up $9.15 or 21.20%, on the Nasdaq. The stock opened its trading at $44.11 after closing Monday's trading at $43.16. The stock has traded between $32.96 and $195.99 in the past 52 week period.

Mirati Therapeutics announced the results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study of intracranial responses of adagrasib in KRASG12C-mutated non-small cell lung cancer (NSCLC) with active and untreated central nervous system (CNS) metastases.

According to a statement, 25 patients with active, untreated CNS metastases were enrolled in the study and treated with adagrasib 600 mg BID.

Of the radiographically evaluable patients, results showed an IC objective response rate of 32%. Three patients achieved a complete response, and three patients achieved a partial response.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT